Home › Companies › PRME

Prime Medicine

Market cap $699M 181.9M shares (10-Q, Oct 31, 2026) × $3.84 close Nov 17, 2026

Most recent annual filing: 2026-03-03

Pipeline (3 active programs)

Technology platforms

Prime Editing · The Broad Institute

Versatile, precise, and efficient gene editing technology platform used to develop in vivo and ex vivo genetic therapies; disease focus includes genetic liver diseases, cystic fibrosis, and CAR-T-based hematology/immunology/oncology programs

Prime Editing · Bristol Myers Squibb

Proprietary Prime Editing gene editing platform — versatile, precise, and efficient technology capable of repairing nearly all types of genetic mutations across tissues including liver, lung, and immune cells; focus areas include liver genetic diseases (Wilson's Disease, Alpha-1 Antitrypsin Deficiency), Cystic Fibrosis, and hematology/immunology/oncology CAR-T development

Prime Editing

Prime Editing gene editing technology platform — versatile, precise, and efficient gene editing enabling one-time curative treatments for diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Supports in vivo liver programs (Wilson disease, AATD, Cystic Fibrosis) via universal liver lipid nanoparticle delivery, and ex vivo CAR-T programs in hematology, immunology, and oncology.

PASSIGE · Bristol Myers Squibb

Targeted full gene insertion platform enabling single super-exon insertion; non-viral, single-step editing approach for CAR-T and Cystic Fibrosis; designed to address nearly all CF patients and enable multiplex CAR-T engineering

Targets: CFTR, TRAC

Capital (as filed)

Cash
$54.9M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$6.3M Sep 30, 2026
Operating cash flow
−$36.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (1 call)

Every verdict Biotech Distilled has published on Prime Medicine, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Prime Medicine (PRME) - Scientific Deep Dive for PM577a, PM647, PM359 and Pipeline Products Prime has the best clinical evidence in gene editing but no issued patents, a going-concern note, $168M of non-cancellable rent, and prices in vivo liver prime editing working on one dosed patient and a mouse — wait for a human pharmacodynamic datapoint or a materially lower price.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (18)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. No press release captured yet; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)